journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/27908825/egfr-mutation-subtypes-influence-survival-outcomes-following-first-line-gefitinib-therapy-in-advanced-asian-nsclc-patients
#1
Natalia Sutiman, Shao Weng Tan, Eng Huat Tan, Wan Teck Lim, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Mei Kim Ang, Wan Ling Tan, Chee Keong Toh, Balram Chowbay
INTRODUCTION: Activating mutations in the EGFR gene have been shown to confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. However, wide inter-patient variability in treatment outcomes to EGFR TKIs in these patients remains unaccounted for. This study aimed to evaluate the influence of EGFR mutation types and subtypes on survival outcomes in advanced Asian NSCLC patients receiving first-line gefitinib therapy. METHODS: Patients with stage IIIB/IV, harboring EGFR mutations, receiving first-line gefitinib treatment and of Asian descent (N=383) were evaluated...
November 28, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27903463/her2-transmembrane-mutations-v659-g660-that-stabilize-homo-and-hetero-dimerization-are-rare-oncogenic-drivers-in-lung-adenocarcinoma-that-respond-to-afatinib
#2
Sai-Hong Ignatius Ou, Alexa B Schrock, Eduard V Bocharov, Samuel J Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa Johnson, Barbara J Gitlitz, Jon Chung, Paulo V Campregher, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, James H Suh, Siraj M Ali, Vamsidhar Velcheti
INTRODUCTION: HER2 transmembrane domain (TMD) mutations (HER2(V659E), HER2(G660D)) have previously been identified in lung adenocarcinomas, but their frequency and clinical significance is unknown. METHODS: We prospectively analyzed 8,551 consecutive lung adenocarcinomas using hybrid-capture based comprehensive genomic profiling (CGP) at the request of the individual treating physicians for the purpose of making therapy decisions. RESULTS: We identified 15 cases (0...
November 26, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27903462/radiomic-based-pathological-response-prediction-from-primary-tumors-and-lymph-nodes-in-nsclc
#3
Thibaud P Coroller, Vishesh Agrawal, Elizabeth Huynh, Vivek Narayan, Stephanie W Lee, Raymond H Mak, Hugo J W L Aerts
INTRODUCTION: Non-invasive biomarkers that capture the total tumor burden could provide important complementary information for precision medicine to aid clinical decision-making. We investigated the value of radiomic data, extracted from pre-treatment computed tomography (CT) images of the primary tumor and lymph nodes, in predicting pathological response following neoadjuvant chemoradiation prior to surgery. METHODS: Eighty-five patients with resectable locally-advanced (stage II-III) non-small cell lung cancer (NSCLC) (median age: 60...
November 26, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27890494/neuroendocrine-tumors-of-the-lung-current-challenges-and-advances-in-the-diagnosis-and-management-of-well-differentiated-disease
#4
REVIEW
Andrew E Hendifar, Alberto M Marchevsky, Richard Tuli
Neuroendocrine tumors (NET) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs and gastrointestinal tract. Lung NET can be classified as well-differentiated (low-grade typical carcinoids [TC] and intermediate-grade atypical carcinoids [AC]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma or small cell lung carcinoma). The incidence of these tumors is increasing, but disease awareness remains low among thoracic specialists who are often involved in the diagnosis and early treatment for these patients...
November 23, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27876675/a-phase-1-1b-study-evaluating-trametinib-plus-docetaxel-or-pemetrexed-in-patients-with-advanced-non-small-cell-lung-cancer
#5
David R Gandara, Natasha Leighl, Jean-Pierre Delord, Fabrice Barlesi, Jaafar Bennouna, Gerald Zalcman, Jeffrey R Infante, Karen L Reckamp, Karen Kelly, Frances A Shepherd, Julien Mazieres, Filip Janku, Olivia S Gardner, Bijoyesh Mookerjee, Yuehui Wu, Donna S Cox, Dan Schramek, Vijay Peddareddigari, Yuan Liu, Anthony M D'Amelio, George Blumenschein
PURPOSE: This 2-part study evaluated trametinib, a MEK1/2 inhibitor, in combination with anticancer agents. Inhibition of MEK, a downstream effector of KRAS, demonstrated preclinical synergy with chemotherapy in KRAS-mutant non-small cell cancer (NSCLC) cell lines. Part 1 of this study identified recommended phase 2 doses of trametinib combinations. Part 2, reported herein, evaluated safety, tolerability, pharmacokinetics, and efficacy of trametinib combinations in patients with NSCLC with and without KRAS mutations...
November 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27876674/brief-report-a-survey-of-thymic-carcinoma-management-patterns-among-international-thymic-malignancy-interest-group-itmig-physicians-with-consensus-from-the-thymic-carcinoma-working-group
#6
Annemarie Shepherd, Gregory Riely, Frank Detterbeck, Charles B Simone, Usman Ahmad, James Huang, Robert Korst, Arun Rajan, Andreas Rimner
INTRODUCTION: Thymic carcinomas are rare epithelial malignancies with limited data to guide management. METHODS: In order to identify areas of agreement and variability in current clinical practice, a 16-question electronic survey was given to members of the International Thymic Malignancy Interest Group (ITMIG). Areas of controversy were discussed with the Thymic Carcinoma Working Group and consensus was achieved, as described. RESULTS: One hundred ITMIG members responded...
November 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27867003/prognostic-impact-of-newly-proposed-m-descriptors-in-tnm-classification-of-non-small-cell-lung-cancer
#7
Junghoon Shin, Bhumsuk Keam, Miso Kim, Young Sik Park, Tae Min Kim, Dong-Wan Kim, Young Whan Kim, Dae Seog Heo
INTRODUCTION: The International Association for the Study of Lung Cancer recently proposed new M descriptors for the next edition of the TNM classification for NSCLC, subdividing the current M1b category into two subcategories: M1b, which indicates a solitary extrathoracic metastasis in a single organ, and M1c, which indicates multiple extrathoracic metastasis. The purpose of this study was to validate the prognostic value of the newly proposed M descriptors in an independent cohort with multivariate and subgroup analysis...
November 17, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27867002/trametinib-plus-4-methylumbelliferone-exhibits-antitumor-effects-by-erk-blockade-and-cd44-downregulation-and-affects-pd1-and-pd-l1-in-malignant-pleural-mesothelioma
#8
Hiroyuki Cho, Seiji Matsumoto, Yoshiko Fujita, Ayumi Kuroda, Toshi Menju, Makoto Sonobe, Nobuyuki Kondo, Ikuko Torii, Takashi Nakano, Primo N Lara, David R Gandara, Hiroshi Date, Seiki Hasegawa
INTRODUCTION: Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy in which the mitogen-activated protein kinase (MAPK) pathway plays a critical role in the regulation of tumorigenesis. Hyaluronan (HA) is a major component of the extracellular matrix, and elevated HA levels, with a concurrent increase in malignant properties, are associated with MPM. METHODS: We evaluated the effects of trametinib, a MAPK kinase enzyme (MEK) inhibitor, and 4-methylumbelliferone (4-MU), an HA synthesis inhibitor, alone and in combination on MPM cells in vitro and in vivo...
November 17, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27865872/thymic-hyperplasia-after-treatment-of-acth-dependent-cushing-s-syndrome-can-be-mistaken-for-a-thymic-epithelial-tumor
#9
Jaydira Del Rivero, Chul Kim, Mary Eid, Mark A Ahlman, Lynnette Nieman, Arun Rajan
No abstract text is available yet for this article.
November 16, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27865871/clinical-impact-of-hybrid-capture-based-next-generation-sequencing-on-changes-in-treatment-decisions-in-lung-cancer
#10
Anna Belilovski Rozenblum, Maya Ilouze, Elizabeth Dudnik, Addie Dvir, Lior Soussan-Gutman, Smadar Geva, Nir Peled
INTRODUCTION: Targeted therapy significantly prolongs survival in lung adenocarcinoma. Current diagnostic guidelines include only EGFR and ALK testing. Next-generation sequencing (NGS) reveals more actionable genomic alterations (GAs) than stan dard diagnostic methods. Data on the influence of hybrid capture-based (HC-based) NGS on treatment are limited, and we investigated its impact on treatment decisions/clinical outcomes. METHODS: This retrospective study included patients with advanced lung cancer on whom HC-based NGS was performed between 11/2011-10/2015...
November 9, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27836576/establishment-of-a-conditional-transgenic-mouse-model-recapitulating-eml4-alk-positive-human-non-small-cell-lung-cancer
#11
Kyoung Ho Pyo, Sun Min Lim, Hye Ryun Kim, Young Hoon Sung, Mi Ran Yun, Sung-Moo Kim, Hwan Kim, Han Na Kang, Ji Min Lee, Sang Gyun Kim, Chae Won Park, Hyun Chang, Hyo Sup Shim, Han-Woong Lee, Byoung Chul Cho
BACKGROUND: ALK fusion is a distinct molecular subclassification of non-small-cell lung cancer (NSCLC) that is targeted by ALK inhibitors. We established a transgenic mouse model that expresses tumors highly resembling human NSCLC harboring EML-ALK fusion. We aimed to test EML4-ALK transgenic mouse model as a platform for assessing efficacy of ALK inhibitor and examining mechanisms of acquired resistance to ALK inhibitor. MATERIALS AND METHODS: Transgenic mouse lines harboring LoxP-STOP-LoxP- FLAG tagged human EML4-ALK (variant 1) transgene was established using C57BL/6N mice...
November 8, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27826035/comprehensive-computational-pathological-image-analysis-predicts-lung-cancer-prognosis
#12
Xin Luo, Xiao Zang, Lin Yang, Junzhou Huang, Faming Liang, Jaime Rodriguez Canales, Ignacio I Wistuba, Adi Gazdar, Yang Xie, Guanghua Xiao
INTRODUCTION: Pathological examination of histopathological slides is a routine clinical procedure for lung cancer diagnosis and prognosis. Although the classification of lung cancer has been updated to become more specific, only a small subset of the total morphological features is taken into consideration. The vast majority of the detailed morphological features of tumor tissues, particularly tumor cells' surrounding microenvironment, are not fully analyzed. The heterogeneity of tumor cells and close interactions between tumor cells and their microenvironments are closely related to tumor development and progression...
November 4, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27826034/multi-institutional-prospective-study-of-reirradiation-with-proton-beam-radiotherapy-for-locoregionally-recurrent-non-small-cell-lung-cancer
#13
Hann-Hsiang Chao, Abigail T Berman, Charles B Simone, Christine Ciunci, Peter Gabriel, Haibo Lin, Stefan Both, Corey Langer, Kristi Lelionis, Ramesh Rengan, Stephen M Hahn, Kiran Prabhu, Marcio Fagundes, William Hartsell, Rosemarie Mick, John P Plastaras
PURPOSE: The management of recurrent non-small cell lung cancer (NSCLC) in the setting of prior radiation therapy is challenging. Proton radiotherapy (PRT) is ideally suited to minimize toxicity to previously irradiated organs. We report the safety/feasibility of PRT for NSCLC reirradiation in a prospective multi-institutional study. MATERIALS AND METHODS: Between 10/2010-12/2015, 57 patients with recurrent NSCLC in/near their prior radiation field were treated at three proton centers...
November 4, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27815126/programmed-cell-death-ligand-pd-l1-expression-in-stage-ii-and-iii-lung-adenocarcinomas-and-nodal-metastases
#14
Hironori Uruga, Emine Bozkurtlar, Tiffany G Huynh, Alona Muzikansky, Yasushi Goto, Maria Gomez-Caraballo, Aaron N Hata, Justin F Gainor, Eugene J Mark, Jeffrey A Engelman, Michael D Lanuti, Mari Mino-Kenudson
INTRODUCTION: PD-L1 expression by immunohistochemistry (IHC) may serve as a predictive biomarker for anti-PD-1/PD-L1 therapies; however, little is known about intertumoral heterogeneity of PD-L1 expression by IHC in lung adenocarcinomas (ADC), and there have been conflicting results on the prognostic role of PD-L1 expression in ADC. METHODS: PD-L1expression was evaluated in resected stage II and III ADC using various cutoffs, and was correlated with clinicopathologic parameters and survival...
November 1, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27810391/cancer-of-the-esophagus-and-esophagogastric-junction-an-8th-edition-staging-primer
#15
Thomas W Rice, Hemant Ishwaran, Mark K Ferguson, Eugene H Blackstone, Peter Goldstraw
This primer for 8th edition staging of esophageal and esophagogastric epithelial cancers presents separate classifications for clinical (cTNM), pathologic (pTNM), and postneoadjuvant pathologic (ypTNM) stage groups, which are no longer shared. For pTNM, pT1 has been subcategorized as pT1a and pT1b for subgrouping pStage I adenocarcinoma and squamous cell carcinoma. A new, simplified esophagus-specific regional lymph node map has been introduced. Undifferentiated histologic grade (G4) has been eliminated; additional analysis is required to expose histopathologic cell type...
October 31, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27794501/targeting-met-in-lung-cancer-will-expectations-finally-be-met
#16
REVIEW
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge
The mesenchymal epithelial transition factor receptor (MET) is a potential therapeutic target in a number of cancers, including non-small cell lung cancer (NSCLC). In NSCLC, MET pathway activation is thought to occur via a diverse set of mechanisms that influence properties affecting cancer cell survival, growth, and invasiveness. Preclinical and clinical evidence suggest a role for MET activation as both a primary oncogenic driver in subsets of lung cancer, and as a secondary driver of acquired resistance to targeted therapy in other genomic subsets...
October 26, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27794500/local-control-and-toxicity-of-a-simultaneous-integrated-boost-for-dose-escalation-in-locally-advanced-esophageal-cancer-interim-results-from-a-prospective-phase-i-ii-trial
#17
James W Welsh, Steven N Seyedin, Pamela K Allen, Wayne L Hofstetter, Jaffer A Ajani, Joe Y Chang, Daniel R Gomez, Arya Amini, Stephen G Swisher, Mariela A Blum, Ahmed I Younes, Quynh-Nhu Nguyen, Bruce D Minsky, Jeremy J Erasmus, Jeffrey H Lee, Manoop Bhutani, Ritsuko U Komaki
INTRODUCTION: Approximately 50% of recurrences after standard-dose chemoradiation for locally advanced esophageal cancer occur within the gross tumor volume (GTV). In this prospective phase I/II clinical trial, we explored use of a simultaneous integrated boost (SIB) dose to the GTV. METHODS: Forty-four patients with unresectable esophageal cancer received chemoradiation with an SIB of 58.8-63 Gy to the GTV and 50.4 Gy to the PTV, all in 28 fractions, with 5 weeks of concurrent docetaxel and fluorouracil or capecitabine...
October 26, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27793774/oncogenic-potential-of-cyp24a1-in-lung-adenocarcinoma
#18
Hiroe Shiratsuchi, Zhuwen Wang, Guoan Chen, Paramita Ray, Jules Lin, Zhuo Zhang, Lili Zhao, David Beer, Dipankar Ray, Nithya Ramnath
INTRODUCTION: We have previously demonstrated that a subset of lung cancer cells express higher CYP24A1 mRNA, a metabolizing enzyme for 1,25-D3, compared to benign tumors or surrounding normal lung and that high CYP24A1 mRNA expression is associated with poor prognosis in resected lung adenocarcinoma (AC). We hypothesized that CYP24A1 has oncogenic potential and increased CYP24A1 expression may contribute to tumor growth, whereas, CYP24A1 targeting may reduce tumor burden. METHODS: Two low CYP24A1 expressing human lung cancer cell lines (SK-LU-1 and Calu-6) were stably transfected either with an empty lentiviral vector or with the CYP24A1 expressing vector...
October 26, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27793776/case-control-study-smoking-history-affects-the-production-of-tumor-antigen-specific-antibodies-ny-eso-1-in-patients-with-lung-cancer-in-comparison-with-cancer-disease-free-group
#19
Dagmar Myšíková, Irena Adkins, Hradilová Naďa, Palata Ondřej, Jan Šimonek, Jiří Pozniak, Jan Kolařík, Anna Skallová-Fialová, Radek Špíšek, Robert Lischke
INTRODUCTION: Lung cancer is the leading cause of cancer mortality worldwide therefore understanding the biological or clinical role of tumor associated antigens and autoantibodies is of an eminent interest for designing anti-tumor immunotherapeutic strategies. METHODS: Here we prospectively analyzed the serum frequencies of NY-ESO-1, Her2/neu and MAGE-A4 antibodies and corresponding antigens expression in tumors of 121 non-small cell lung (NSCLC) patients undergoing surgery without prior neoadjuvant chemotherapy and compared them with 57 control age-matched patients with no history of a malignant disease...
October 25, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27793775/systemic-and-tumor-th1-and-th2-inflammatory-profile-and-macrophages-in-lung-cancer-influence-of-underlying-chronic-respiratory-disease
#20
Mercè Mateu-Jimenez, Víctor Curull, Lara Pijuan, Albert Sánchez-Font, Hugo Rivera-Ramos, Alberto Rodríguez-Fuster, Rafael Aguiló, Joaquim Gea, Esther Barreiro
INTRODUCTION: Chronic respiratory conditions, especially chronic obstructive pulmonary disease (COPD), and inflammatory events underlie lung cancer (LC). We hypothesized that profiles of T helper 1 and T helper 2 cytokines and type 1 and type 2 macrophages (M1 and M2) are differentially expressed in lung tumors and blood of patients with NSCLC with and without COPD and that the ratio M1/M2 specifically may influence their survival. METHODS: In blood, inflammatory cytokines (determined by enzyme-linked immunosorbent assay) were quantified in 80 patients with LC (60 with LC and COPD [the LC-COPD group] and 20 with LC only [the LC-only group]) and lung specimens (tumor and nontumor) from those undergoing thoracotomy (20 in the LC-COPD group and 20 in the LC-only group)...
October 25, 2016: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"